EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial



Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial



Journal of the Neurological Sciences 238(1-2): 31-39



Background: A multicenter, double-blind, placebo-controlled study was conducted to assess the efficacy and safety of fasudil, a Rhokinase inhibitor (RKI), in the treatment of acute ischemic stroke.Methods: A total of 160 patients, who were able to receive drug treatment within 48 h of acute ischemic stroke onset were enrolled. Patients received either 60 mg fasudil or a placebo (saline) by intravenous injection over 60 min, twice daily for 14 days. The primary end points were neurological status at 2 weeks after the start of treatment, and clinical outcome at I month after the onset of symptoms.Results: Fasudil treatment resulted in significantly greater improvements in both neurological functions (p = 0.0013), and clinical outcome (p = 0.0015). There were no serious adverse events reported in the fasudil group. The average trough value (12 h values) of active metabolite hydroxyfasudil, another RKI, in healthy elderly volunteers receiving 60 mg of fasudil was 0.077 mu M-a concentration well above that needed to inhibit Rho-kinase (0.025-0.05 mu M).Conclusion: Treatment with fasudil-within 48 h of acute ischemic stroke onset significantly improved the patient's clinical outcome. This study found fasudil to be a useful and safe drug for patients with acute ischemic stroke. Further evaluations, for example, 3-month functional outcomes in a larger clinical trial, may help to define the efficacy of fasudil in acute ischemic stroke. (c) 2005 Elsevier B.V All rights reserved.

(PDF emailed within 0-6 h: $19.90)

Accession: 012014872

Download citation: RISBibTeXText

PMID: 16005902

DOI: 10.1016/j.jns.2005.06.003



Related references

Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke 43(3): 630-636, 2012

The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke 31(4): 811-816, 2001

Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial. Stroke 29(1): 12-17, 1998

Lubeluzole in acute ischemic stroke: A double-blind, placebo-controlled phase II trial. Stroke 27(1): 76-81, 1996

A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 25(7): 1348-1353, 1994

BNG-1 in the Recovery of Acute Ischemic Stroke: A phase 2, Double-blind, Placebo-controlled Randomized Trial. Acta Neurologica Taiwanica 24(3)(): 73-81, 2016

Diazepam to improve acute stroke outcome: results of the early GABA-Ergic activation study in stroke trial. a randomized double-blind placebo-controlled trial. Cerebrovascular Diseases 21(1-2): 120-127, 2005

The Membrane-Activated Chelator Stroke Intervention (MACSI) Trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal phase III study. International Journal of Stroke 6(4): 362-367, 2011

A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT). Stroke 40(11): 3518-3525, 2009

Cervene in acute ischemic stroke: results of a double-blind, placebo-controlled, dose-comparison study. Journal of Stroke and Cerebrovascular Diseases 8(4): 224-230, 2007

Prevention of poststroke depression with milnacipran in patients with acute ischemic stroke: a double-blind randomized placebo-controlled trial. International Clinical Psychopharmacology 26(5): 263-267, 2012

Prospective randomized placebo-controlled double-blind clinical study comparing the safety and efficacy of heparin and nadroparin administered in therapeutic doses to placebo in acute ischemic stroke - pilot study. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia (): -, 2016

The effect of Ginkgo biloba on functional outcome of patients with acute ischemic stroke: a double-blind, placebo-controlled, randomized clinical trial. Journal of Stroke and Cerebrovascular Diseases 22(8): E557-E563, 2015

The rtPA 0- to 6-hour acute stroke trial, part A Results of a double-blind, placebo-controlled, multicenter study. Stroke 31(4): 811-816, April, 2000

A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Seminars in Thrombosis and Hemostasis 16 Suppl: 25-33, 1990